Equities research analysts at Oppenheimer started coverage on shares of Outlook Therapeutics (NASDAQ:OTLK) in a research report issued on Thursday, Briefing.com Automated Import reports. The firm set an “outperform” rating and a $12.00 price target on the stock.
Several other analysts have also weighed in on OTLK. ValuEngine raised Outlook Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, March 20th. Ascendiant Capital Markets began coverage on Outlook Therapeutics in a research report on Monday, April 22nd. They set a “buy” rating and a $4.00 target price for the company.
OTLK opened at $1.03 on Thursday. Outlook Therapeutics has a 12-month low of $0.85 and a 12-month high of $10.96.
Outlook Therapeutics (NASDAQ:OTLK) last released its earnings results on Wednesday, May 15th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.66) by $0.08.
A hedge fund recently bought a new stake in Outlook Therapeutics stock. Renaissance Technologies LLC purchased a new position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 11,166 shares of the company’s stock, valued at approximately $83,000. Renaissance Technologies LLC owned 0.10% of Outlook Therapeutics at the end of the most recent quarter. Institutional investors own 4.60% of the company’s stock.
About Outlook Therapeutics
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Recommended Story: Call Option Volume
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.